Banque Pictet & Cie SA Sells 83,130 Shares of Abbott Laboratories $ABT

Banque Pictet & Cie SA lessened its stake in Abbott Laboratories (NYSE:ABT) by 37.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 139,532 shares of the healthcare product maker’s stock after selling 83,130 shares during the quarter. Banque Pictet & Cie SA’s holdings in Abbott Laboratories were worth $17,482,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its position in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the period. Sivia Capital Partners LLC raised its holdings in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares during the period. United Bank lifted its stake in Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after purchasing an additional 2,001 shares during the last quarter. Edgestream Partners L.P. bought a new position in Abbott Laboratories during the second quarter worth about $404,000. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Abbott Laboratories by 134.2% during the second quarter. Arrowstreet Capital Limited Partnership now owns 509,565 shares of the healthcare product maker’s stock worth $69,306,000 after purchasing an additional 291,987 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Trading Down 0.3%

Shares of NYSE:ABT opened at $102.41 on Thursday. Abbott Laboratories has a 12-month low of $100.88 and a 12-month high of $139.06. The business has a 50 day moving average of $109.68 and a 200-day moving average of $121.44. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The stock has a market cap of $178.36 billion, a PE ratio of 27.53, a P/E/G ratio of 1.64 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Analysts Set New Price Targets

Several analysts have issued reports on ABT shares. Royal Bank Of Canada dropped their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Raymond James Financial decreased their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Daiwa Securities Group reduced their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Finally, Sanford C. Bernstein decreased their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $135.68.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott joined a $575M funding round for wearable maker Whoop as a strategic investor, positioning ABT to participate in consumer health/wearables and personalized‑health data opportunities that could broaden diagnostics and subscription revenue pathways. Abbott joins $575M funding round for wearable maker Whoop
• Positive Sentiment: Abbott integrated its Precision Oncology testing portfolio into Flatiron’s OncoEMR, improving workflow for oncology providers and potentially raising test ordering and revenue capture in oncology diagnostics. Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR
• Positive Sentiment: Analyst optimism: Seeking Alpha noted a rating upgrade into Q1 earnings, suggesting some analysts see improving fundamentals and an attractive entry point after recent weakness. Upgrades can help limit downside and attract value buyers. Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade)
• Neutral Sentiment: Analyst commentaries and comparisons (GEHC vs ABT and sector roundups) are driving attention but not a clear consensus; some authors highlight valuation appeal while noting macro and currency risks. GEHC or ABT: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Investor guides and sector lists name Abbott among steady healthcare picks for long‑term growth (dividend history, nutrition and Libre growth cited), supporting longer‑term investor interest even if near‑term volatility persists. Best Healthcare Stocks to Buy Right Now for Long-Term Growth
• Negative Sentiment: Analyst actions and comments are mixed: BTIG cut its price target (though maintained a Buy), signaling revised near‑term expectations; downward PT moves can pressure the stock. BTIG lowers price target on Abbott
• Negative Sentiment: Market concern about a recent soft quarter and a revenue miss (and the stock’s slide from its 52‑week high) is keeping selling pressure; near‑term headwinds include currency and macro uncertainty. This Dividend King Is Down 26%. When Will It Bounce Back?
• Negative Sentiment: Short‑term price action: coverage noting recent daily dips and lower trading volume versus average suggests current momentum is weak despite the strategic positives. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Insider Buying and Selling

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. The trade was a 2.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last 90 days. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.